GENFLOW BIOSCIENCES PLC (WQ5) - Net Assets

Latest as of June 2025: €-303.00K EUR ≈ $-354.24K USD

Based on the latest financial reports, GENFLOW BIOSCIENCES PLC (WQ5) has net assets worth €-303.00K EUR (≈ $-354.24K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€468.38K ≈ $547.59K USD) and total liabilities (€771.38K ≈ $901.83K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GENFLOW BIOSCIENCES PLC (WQ5) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-303.00K
% of Total Assets	-64.69%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	2038.2

GENFLOW BIOSCIENCES PLC - Net Assets Trend (2021–2024)

This chart illustrates how GENFLOW BIOSCIENCES PLC's net assets have evolved over time, based on quarterly financial data. Explore WQ5 cash generation efficiency to assess how effectively this company generates cash.

Annual Net Assets for GENFLOW BIOSCIENCES PLC (2021–2024)

The table below shows the annual net assets of GENFLOW BIOSCIENCES PLC from 2021 to 2024. For live valuation and market cap data, see WQ5 stock market capitalisation.

Year	Net Assets	Change
2024-12-31	€-403.01K ≈ $-471.16K	-180.65%
2023-12-31	€499.69K ≈ $584.19K	-78.88%
2022-12-31	€2.37 Million ≈ $2.77 Million	+4193.00%
2021-12-31	€55.12K ≈ $64.45K	--

Equity Component Analysis

This analysis shows how different components contribute to GENFLOW BIOSCIENCES PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 478290500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€5.19 Million	%
Total Equity	€-403.01K	100.00%

GENFLOW BIOSCIENCES PLC Competitors by Market Cap

The table below lists competitors of GENFLOW BIOSCIENCES PLC ranked by their market capitalization.

Company	Market Cap
Energys Group Limited Ordinary Shares NASDAQ:ENGS	$13.67 Million
Vesuvius PLC LSE:VSVS	$13.67 Million
Neungyule Education Inc KQ:053290	$13.68 Million
Photomyne Ltd TA:PHTM	$13.70 Million
Triton Holding Public Company Limited BK:TRITN	$13.65 Million
Grainger PLC LSE:GRI	$13.63 Million
Ata Gayrimenkul Yatirim Ortakligi AS IS:ATAGY	$13.62 Million
CMX GOLD+SILVER CORP. F:6GS	$13.61 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GENFLOW BIOSCIENCES PLC's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 499,693 to -403,008, a change of -902,701 (-180.7%).
Net loss of 1,587,235 reduced equity.
New share issuances of 656,635 increased equity.
Other factors increased equity by 27,899.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-1.59 Million	-393.85%
Share Issuances	€656.63K	+162.93%
Other Changes	€27.90K	+6.92%
Total Change	€-	-180.65%

Book Value vs Market Value Analysis

This analysis compares GENFLOW BIOSCIENCES PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	€0.00	€0.02	x
2022-12-31	€0.01	€0.02	x
2023-12-31	€0.00	€0.02	x
2024-12-31	€0.00	€0.02	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GENFLOW BIOSCIENCES PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-555.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	-1792.68%	0.00%	0.00x	5.02x	€-993.71K
2022	-56.43%	0.00%	0.00x	1.11x	€-1.57 Million
2023	-372.30%	0.00%	0.00x	2.14x	€-1.91 Million
2024	0.00%	0.00%	0.00x	0.00x	€-1.55 Million

Industry Comparison

This section compares GENFLOW BIOSCIENCES PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $2,083,584,994
Average return on equity (ROE) among peers: -84.09%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GENFLOW BIOSCIENCES PLC (WQ5)	€-303.00K	-1792.68%	N/A	$13.66 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$49.37 Million	-85.44%	1.28x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$3.94 Million	-301.40%	1.87x	$161.62 Million
Theravance Biopharma Inc (0TB)	$-223.84 Million	0.00%	0.00x	$787.91 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$230.94 Million	-20.03%	0.13x	$197.40 Million
PreveCeutical Medical Inc (18H)	$-344.34K	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$538.39 Million	-12.38%	0.07x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$32.50 Million	-376.16%	5.37x	$1.14 Billion
BIOCURE TECHNOLOGY INC. (1WH)	$-2.33 Million	0.00%	0.00x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$796.12 Million	-42.03%	0.30x	$1.82 Billion
BioNTech SE (22UA)	$19.41 Billion	-3.43%	0.16x	$20.05 Billion

About GENFLOW BIOSCIENCES PLC

F:WQ5 Germany Biotechnology

Market Cap

$14.40 Million

€12.32 Million EUR

Market Cap Rank

#26213 Global

#2272 in Germany

Share Price

€0.02

Change (1 day)

+0.00%

52-Week Range

€0.01 - €0.03

All Time High

€0.16